Skip to content Skip to sidebar Skip to footer
Subscribe Now
NEWS
ImmunityBio Reveals P-II (QUILT-3.055) Trial Findings of Anktiva in CPI-Resistant NSCLC
Shots: ImmunityBio has reported P-II (QUILT-3.055) trial data assessing Anktiva (nogapendekin alfa inbakicept-pmln) + checkpoint inhibitor immunotherapy (CPI) in CPI-resistant advanced NSCLC Among 86 pts (51% 2L, 49% 3L+), mOS was 14.3mos. (23 alive at Dec 2025); 69/86 achieving ALC ≥1,200 had mOS of 15.8 vs 11.5mos. in non-achievers, while baseline ALC ≥1,200 & mean…
September 9, 20250Comments
NEWS
Amgen and Kyowa Kirin Report Topline P-III (ASCEND) Study Results of Rocatinlimab in Moderate to Severe Atopic Dermatitis
Shots: The P-III (ASCEND) trial evaluated rocatinlimab (150 or 300mg, Q4W/Q8W) in ~2,600 atopic dermatitis pts who completed 24wks. in ROCKET trial program & continued for 32wks. in ASCEND, which will evaluate long-term safety & efficacy up to 104wks. Trial showed a favorable long-term safety profile (1EP) with low discontinuation rates due to AEs, consistent…
September 9, 20250Comments
NEWS
Novartis to Acquire Tourmaline Bio for ~$1.4B, Complementing its Cardiovascular Portfolio
Shots: Novartis has entered into an agreement to acquire Tourmaline Bio, incl. its asset pacibekitug, expanding its cardiovascular portfolio As per the deal, Novartis, through its subsidiary, will acquire Tourmaline for $48/share, representing an aggregate of ~$1.4B, & will merge the subsidiary into Tourmaline upon completion, making it an indirect wholly owned unit of Novartis; closing…
September 9, 20250Comments
Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots
VIEWPOINTS
Unlocking Approval: Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots 
Shots:  The United States has about 38.4 million people living with diabetes, representing 11.6% of the total population. With growing prevalence, there is a significant unmet need for affordable diabetes medications.  Biocon Biologics recently announced the FDA approval of Kirsty, the first and only interchangeable biosimilar to NovoLog (Insulin Aspart).  Joshua Salsi, the Head of…
September 8, 20250Comments
Rick Modi from Affinia Therapeutics in a Stirring Dialogue Exchange with PharmaShots
SPOTLIGHT
CXO Talks: Rick Modi from Affinia Therapeutics in a Stirring Dialogue Exchange with PharmaShots
Shots: In this episode of the CXO Talks podcast, PharmaShots speaks with Rick Modi, CEO at Affinia Therapeutics Driven by cutting-edge innovation, Affinia is pioneering and re-imagining adeno-associated virus serotype 9 (AAV9), a gene therapy delivery method for conditions affecting cardiac muscle, skeletal muscle, and the central nervous system Rick articulates the diagnostic and therapeutic…
September 8, 20250Comments
Eli lilly
NEWS
Eli Lilly Reports P-III (BRUIN CLL-313) Trial Data on Jaypirca for 1L Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shots: Eli Lilly has reported P-III (BRUIN CLL-313) trial data assessing Jaypirca (pirtobrutinib; 200mg, PO, QD) vs chemoimmunotherapy (bendamustine + rituximab) in 282 pts with 1L chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions Trial met its 1EP of improved PFS per IRC, while OS was immature but showed a favorable trend &…
September 8, 20250Comments
Astrazeneca
NEWS
AstraZeneca Reports P-III (FLAURA2) Trial Findings on Tagrisso Regimen to Treat EGFRm NSCLC
Shots: AstraZeneca has reported P-III (FLAURA2) trial findings on Tagrisso + Pt-based CT as a 1L treatment of pts with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC The P-III (FLAURA2) trial assessed Tagrisso (80mg, QD, PO) + pemetrexed + cisplatin/carboplatin (Q3W for 4 cycles) followed by Tagrisso + pemetrexed maintenance (Q3W) vs…
September 8, 20250Comments